alemtuzumab
Sign in to saveAlso known as Campath-1H, Campath, Campath Mabcampath, Lemtrada, LDP-03
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.
In the Vinony graph
Within Vinony's link graph, alemtuzumab is referenced by 583 other articles, and connects out to intravenous infusion and defusion, fusion protein and humanized antibody.
It sits within the topics Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drugboxes which contain changes to watched fields.
Its subject is documented across 25 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477317070
- Drug.type
- mab
- Drug.image
- Alemtuzumab Fab 1CE1.png
- Drug.mab_type
- mab
- Drug.source
- zu/a
- Drug.target
- CD52
- Drug.tradename
- Campath, Mabcampath, Lemtrada, others
- Drug.MedlinePlus
- a608053
- Drug.DailyMedID
- Alemtuzumab
- Drug.pregnancy_AU
- B3
- Drug.pregnancy_AU_comment
- (Lemtrada); B2 (Mabcampath)
- Drug.routes_of_administration
- Intravenous infusion
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG06
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2001
- Admin. routes
- parenteral
- Indications
- acute graft vs. host disease, chronic lymphocytic leukemia, acute lymphoblastic leukemia, unspecified peripheral T-cell lymphoma
via ChEMBL · EBI
Research
3,947 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Mass
- 145453.8
- Has use
- medication
Show 8 more facts
- medical condition treated
- mycosis fungoides
- World Health Organisation international non-proprietary name
- alemtuzumab
- defined daily dose
- 0.13
- subject has role
- monoclonal antibody
- Commons category
- Alemtuzumab
- chemical formula
- C₆₄₆₈H₁₀₀₆₆N₁₇₃₂O₂₀₀₅S₄₀
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~8 min read
Encyclopedic overview
15 sectionsContents
- Medical uses
- Chronic lymphocytic leukemia
- Multiple sclerosis
- Contraindications
- Adverse effects
- Biochemical properties
- History
- Society and culture
- Economics
- Names
- Research
- Antiviral properties
- Graft-versus-host disease
- References
- External links
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.
It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
Excerpted from Wikipedia’s “alemtuzumab” article, available under the CC BY-SA 4.0 licence.